Kiniksa Pharmaceuticals, Ltd. KNSA 深 沪
等待开盘 07-01 09:30:00 美东时间
63.95
+1.540
+2.47%
华盛通- 最 高64.81
- 今 开62.41
- 成交量 130.40万股
- 最 低 61.60
- 昨 收 62.41
- 总市值 49.20亿
- 52周最高 64.81
- 市盈率 静 85.60
- 换手率 1.69%
- 52周最低 26.27
- 委 比 -27.91%
- 总股本 7693.80万
- 历史最高 64.81
- 量 比 0.60
- 振 幅 5.14%
- 历史最低 5.01
- 每 手 1
- 风险率 7.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 康托·菲茨杰拉德大幅上调AMD、英特尔、迈威尔科技、美光、西部数据目标价！Applied、INIO、LFTO、Quantinuum获多家大行首予买入评级
今日重点评级关注：Evercore ISI集团：维持ProQR Therapeutics"跑赢大市"评级，目标价从5美元升至6美元；摩根士丹利：维持霍尼韦尔"标配"评级，目标价从245美元升至490美元
06-30 10:14
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $72
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $59 to $72.
06-29 21:32
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors
Kymera Therapeutics announced the appointment of Felix J. Baker, PhD, as Chairman of the Board, succeeding Bruce Booth, DPhil, who will remain an Independent Director. Dr. Baker has been a strategic partner since 2024, contributing valuable insights as Kymera advances its pipeline and expands its growth. Dr. Baker, a Managing Member of Baker Brothers Investments, holds advanced degrees in Immunology from Stanford University and serves on multiple...
06-24 20:01
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Kiniksa Pharmaceuticals International, plc announced that its management will participate in fireside chats at the 2026 Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9. Live webcasts of the presentations will be available on the company’s website, www.kiniksa.com, with replays accessible within 48 hours. Kiniksa is a biopharmaceutical company focused on developing novel the...
05-29 20:01
Kiniksa Pharmaceuticals Caps Major Shareholder Voting Control Rights
Kiniksa Pharmaceuticals ( ($KNSA) ) has shared an announcement. On May 21, 2026...
05-27 06:09
Kiniksa Pharmaceuticals CSO Resigns and Shifts to Advisor
Kiniksa Pharmaceuticals ( ($KNSA) ) has shared an announcement. On April 30, 20...
05-02 05:55
美股大行评级 | 瑞银：维持Visa"买入"评级！目标价从390美元升至410美元
今日重点评级关注：HC Wainwright & Co.：维持Protara Therapeutics"买入"评级，目标价从23美元升至27美元；BTIG：维持Black Diamond Therapeutic"买入"评级，目标价从10美元升至11美元
04-30 19:24
美股牛股 | 26财年Q2营收翻倍！新美亚电子大涨近15%；美国健康保险巨头康西哥大涨14%
26财年Q2营收翻倍！新美亚电子大涨近15%；美国健康保险巨头康西哥涨14%，Q1盈利大超市场预期>>
04-29 16:13
美股大行评级 | 达美乐比萨惨遭10家大行下调目标价；铿腾电子、艾克尔科技、Relay 、辛普森配件制造、TFI International等获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Intellia Therapeutics"买入"评级，目标价从48美元升至58美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从7美元升至8美元
04-29 10:28
Jefferies Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $71
Jefferies analyst Roger Song maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $58 to $71.
04-29 02:02
